Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
| Autor: | E. Holmgren, S. Shak, R. Benjamin, Susan Stalter, George W. Sledge, Michael S. Gordon, Kim Margolin, M. Talpaz, Daniel C. Adelman |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Vascular Endothelial Growth Factor A Cancer Research medicine.medical_specialty Dose-Response Relationship Immunologic Endothelial Growth Factors Gastroenterology Drug Administration Schedule chemistry.chemical_compound Pharmacokinetics Fludarabine monophosphate Internal medicine Neoplasms Medicine Humans Adverse effect Infusions Intravenous Aged Lymphokines Neovascularization Pathologic business.industry Vascular Endothelial Growth Factors Cancer Antibodies Monoclonal Middle Aged medicine.disease Vascular endothelial growth factor Clinical trial Vascular endothelial growth factor A Oncology chemistry Toxicity Immunology Female business |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(3) |
| ISSN: | 0732-183X |
| Popis: | PURPOSE: We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer. PATIENTS AND METHODS: Cohorts of patients with metastatic cancer having failed prior therapy entered a phase I trial of rhuMAb VEGF administered by a 90-minute intravenous infusion at doses from 0.1 to 10.0 mg/kg on days 0, 28, 35, and 42. Patients underwent pharmacokinetic sampling on day 0 and had serum samples obtained during the subsequent 28 days. Response assessment was carried out on days 49 and 72. RESULTS: Twenty-five patients with a median Eastern Cooperative Oncology Group performance status of 0 were accrued. There were no grade III or IV adverse events definitely related to the antibody. There were three episodes of tumor-related bleeding. Infusions of rhuMAb VEGF were well tolerated without significant toxicity. Grades I and II adverse events possibly or probably related to study drug included asthenia, headache, and nausea. Pharmacokinetics revealed a linear profile with a half-life of 21 days. There were no objective responses, though 12 patients experienced stable disease over the duration of the study. CONCLUSION: rhuMAb VEGF was safely administered without dose-limiting toxicity at doses ranging up to 10 mg/kg. Multiple doses of rhuMAb VEGF were well tolerated, and pharmacokinetic studies indicate that doses of ≥ 0.3 mg/kg have a half-life similar to that of other humanized antibodies. Subsequent trials will explore rhuMAb VEGF alone and in combination chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|